Activation of Expression of p15, p73 and E-Cadherin in Leukemic Cells by Different Concentrations of 5-Aza-2'-Deoxycytidine (Decitabine)

Anticancer Research

Volumn 24, Issue 1, 2004, Pages 75-78

  Farinha, Nuno J ^a,b   Shaker, Sepideh ^a   Lemaire, Maryse ^a   Momparler, Louise ^a   Bernstein, Mark ^a   Momparler, Richard L ^a  

^a UNIVERSITY OF MONTREAL   (Canada)

^b HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

5 aza 2' deoxycytidine; E cadherin; Leukemia; Methylation; p15CDKN2B; p73

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; PROTEIN P15; PROTEIN P73; UVOMORULIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL ASSAY; COLONY FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA METHYLATION; DNA SYNTHESIS INHIBITION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG SCREENING; GENE ACTIVATION; GENE INACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMOGENESIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SILENT GENE;

EID: 1442277103     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Jones PA and Laird PW: Cancer epigenetics comes of age. Nature Genetics 21: 163-167, 1999.
2. Wong IH, Ng MH, Huang DP and Lee JC: Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95: 1942-1949, 2000.
3. Kawano S, Miller CW, Gombart AF, Bartram CR, Matsuo Y, Asou H, Sakashita A, Said J, Tatsumi E and Koeffler HP: Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation. Blood 94: 1113-1120, 1999.
4. Melki JR, Vincent PC, Brown RD and Clark SJ: Hypermethylation of E-cadherin in leukemia. Blood 95: 3208-3213, 2000.
5. Momparler RL and Bovenzi V: DNA methylation and cancer. J Cell Physiol 183: 145-154, 2000.
6. Momparler RL: Molecular, cellular and animal pharmacology of 5-aza-2'-deoxycytidine. Pharmacol Ther 30: 287-299, 1985.
7. Kantarjian HM, O'Brien SM, Keating M, Beran M, Estey E, Giralt S, Kornblau S, Rios MB, de Vos D and Talpaz M: Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 11: 1617-1620, 1997.
8. Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S and Pinto A: 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavorable myelodysplastic syndromes. Leukemia 7: 30-35, 1993.
9. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M and Ferrant A: Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18: 956-962, 2000.
10. Momparler RL, Côté S and Eliopoulos N: Pharmacological approach for optimization of the dose schedule of 5-Aza-2'-deoxycytidine (Decitabine) for therapy of leukemia. Leukemia 11: 175-180, 1997.
11. Primeau M, Gagnon J and Momparler RL: Synergistic antineoplastic action of DNA methylation inhibitor 5-AZA-2'-deoxycytidine and histone deacetylase inhibitor depsipeptide on human breast carcinoma cells. Int J Cancer 103: 177-184, 2003.
12. Dodge JE, Munson C and List AF: KG-1 and KG-1a model the p15 CpG island methylation observed in acute myeloid leukemia patients. Leuk Res 25: 917-925, 2001.
13. Rivard GE, Momparler RL, Demers J, Benoit P, Raymond R, Lin KT and Momparler LF: Phase I study on 5-aza-2'-deoxycytidine in children with acute leukemia. Leuk Res 5: 453-462, 1981.
14. Daskalakis M, Nguyen TT, Nguyen C, Guldberg P, Kohler G, Wjermans P, Jones PA and Lubbert M: Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. Blood 100: 2957-2964, 2002.